ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch MarketApril 28, 2025 9:36 AM EDT | Source: ArcStone US Corp.New York, New York, Dallas, Texas, and Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a leading cross-border financial services firm, today announced the publication of an industry report on the rapidly emerging oral stimulant pouch market — a multi-billio ...

ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch SectorTransaction Marks ArcStone's Continued Cross-Border M&A Franchise Involving a NASDAQ-Listed Company, Underscoring the Strength of Its Global Platform and Financial AcumenApril 25, 2025 10:26 AM EDT | Source: ArcStone US Corp.Transaction Adds Executive Bench ...

DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokele ...

Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace DALLAS, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into a Master Distribution Agreement (the "A ...

Financial Performance - Mangoceuticals, Inc. reported revenues of $615,873 for the year ended December 31, 2024, a decrease of 15.8% compared to $731,493 for the year ended December 31, 2023[604]. - The company's gross profit for 2024 was $379,964, down from $431,501 in 2023, reflecting a gross margin decline[604]. - Total operating expenses decreased to $8,351,957 in 2024 from $9,650,391 in 2023, indicating a reduction of approximately 13.4%[604]. - The net loss for the year ended December 31, 2024, was $8,707,226, compared to a net loss of $9,212,417 in 2023, showing an improvement of about 5.5%[604]. - The basic and diluted loss per share improved to $(4.84) in 2024 from $(8.58) in 2023, reflecting a reduction in loss per share[604]. - Cash used in operating activities for the year ended December 31, 2024, was $4,863,776, an improvement from $6,997,375 in the previous year[616]. - The net loss for the year ended December 31, 2024, was $8,707,226, compared to a net loss of $9,212,417 for the year ended December 31, 2023, indicating a reduction in losses by approximately 5.5%[616]. Cash and Assets - Cash equivalents decreased significantly from $739,006 in 2023 to $58,653 in 2024, a decline of approximately 92.1%[602]. - Total assets increased to $15,370,511 as of December 31, 2024, compared to $1,050,793 in 2023, representing a substantial growth[602]. - The cash and cash equivalents at the end of the period for December 31, 2024, were $58,653, down from $739,006 at the beginning of the period[616]. - As of December 31, 2024, the Company reported total cash of $58,653, down from $739,006 as of December 31, 2023[677]. Financing Activities - The company raised $2,650,000 from the issuance of preferred stock for cash during the year ended December 31, 2024[616]. - The company’s total cash provided by financing activities was $4,128,268 for the year ended December 31, 2024, compared to $7,057,040 in the previous year[616]. - The Company completed an initial public offering in March 2023, issuing 83,333 shares at $60.00 per share, resulting in net proceeds of $4.35 million[624]. - The Follow On Offering closed on December 19, 2023, raising total gross proceeds of $1.2 million from the sale of 266,667 shares at $4.50 per share[631]. - The net proceeds from the Follow On Offering were approximately $1.0 million, allocated for marketing, operational expenses, and working capital[632]. Intangible Assets and Patents - The company has intangible assets of $15,232,617 related to acquired patents as of December 31, 2024[602]. - The Company entered into a Patent Purchase Agreement with Intramont Technologies for patents related to infection prevention, paying $20,000,000, which included 980,000 shares of Series C Convertible Preferred Stock valued at $19,600,000 and $400,000 in cash[649]. - The Company acquired patents from Greenfield Investments for $1,344,150, issuing 515,000 shares of common stock as payment[651]. - As of December 31, 2024, the carrying amount of patents is $15,232,617, with a gross carrying amount of $15,954,150 and accumulated amortization of $721,533[667]. - Amortization expense for the year ended December 31, 2024, was $721,533, with estimated amortization expenses of $1,122,639 for the next five years[668]. - The Company performed annual impairment testing for intangible assets, with no impairment losses recognized for the year ended December 31, 2024[668]. Operational Developments - The Company has developed and marketed a range of men's wellness products, including brands for erectile dysfunction, hair loss, hormone balance, and weight management[619]. - The Company is conducting Phase II clinical trials for its patented respiratory illness prevention technology, with completion expected in Q2 2025[621]. - The Company is preparing to launch its Dermytol brand targeting skin conditions, with operations expected to commence in Q3 2025[622]. Stock and Equity Transactions - The Company executed a 1-for-15 reverse stock split on October 16, 2024, with no effect on the par value or authorized shares[625]. - The Company sold 1,500 shares of Series B Convertible Preferred Stock for $1,650,000, along with warrants to purchase 220,000 shares of common stock[636]. - The Company issued warrants for the purchase of 18,667 shares at an exercise price of $5.70 as part of the Follow On Offering[633]. - The Company designated 6,250,000 shares of Series C Convertible Cumulative Preferred Stock, with 980,000 shares issued and outstanding as of December 31, 2024[738]. - The Company accrued undeclared dividends on Series C Preferred Stock totaling $802,109 during 2024[739]. - The Company issued 28,067 shares of common stock as dividends on Series B Preferred Stock, resulting in a deemed dividend of approximately $70,168[734]. Consulting and Service Agreements - The Company entered into a service agreement with Greentree Financial Group, agreeing to pay $40,000 in cash and issue 5,000 shares of restricted common stock valued at $16.95 per share, totaling $84,752[749]. - The Company entered into a Consulting Agreement with G&P General Consulting, issuing 16,667 shares valued at $4.20 per share for a total of $70,000, for services related to international expansion[758]. - The Company entered into a Consulting Agreement with John Dorsey, agreeing to pay $6,000 per month and issuing 13,333 shares valued at $6.31 per share, totaling $84,180[774]. - A Consulting Agreement with Levo Healthcare Consulting, Inc. was established, involving a cash payment of $6,250 and 13,000 shares valued at $4.35 per share, totaling $56,160[776]. Revenue Recognition and Accounting Policies - The Company follows ASC 606 for revenue recognition, generating online revenue through direct sales on its platform[691]. - The Company has a Physician Services Agreement with Doctegrity for online telemedicine services, accounting for service revenue as a principal[694]. - The Company’s contracts for prescription products include two performance obligations: access to products and consultation services, with revenue recognized upon delivery[693]. - The Company has not yet adopted ASU No. 2023-09, which will require additional disclosures on income tax paid and effective tax rate reconciliation once implemented[685].

Core Viewpoint - Mangoceuticals, Inc. has launched PeachesRx, a women's health and wellness brand, focusing on telemedicine solutions tailored to women's unique health needs, particularly in weight management through GLP-1 receptor agonists [1][2][4]. Market Opportunity - The global GLP-1 market for weight management is projected to exceed $48 billion by 2030, with women making up the majority of users [3]. - The global women's health market was valued at $49.33 billion in 2024 and is expected to reach $68.53 billion by 2030, growing at a 5.1% CAGR [3]. Product Offering - PeachesRx will initially focus on compounded GLP-1 receptor agonists, which are effective for weight loss by regulating appetite and glucose metabolism [2]. - The brand aims to provide accessible and affordable telehealth solutions specifically designed for women's metabolic needs [2][3]. Strategic Positioning - PeachesRx is positioned to capture the growing demand for women's telehealth services, leveraging a HIPAA-compliant telemedicine platform for seamless access to treatments [3][4]. - The company plans to expand its offerings beyond weight management to include areas such as sexual health, hair growth, and hormone therapy in the future [5]. Leadership Insights - The CEO of Mangoceuticals emphasized the opportunity in women's health, noting that over 60% of telehealth users are female, indicating a strong market for personalized healthcare solutions [4][5]. - The COO highlighted the commitment to transforming access to women's healthcare by providing innovative, affordable, and medically supervised treatments [5].

Dallas, Texas, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling a variety of innovative health solutions today announced that it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian influenza viruses (H5N1), specifically within the poultry industry. The Company has engaged Vipragen Biosciences, an AAALAC- ...

Dallas, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, today announced significant progress in its ongoing H1N1 efficacy study conducted by Vipragen Biosciences ("Vipragen"), an AAALAC-accredited preclinical CRO in Mysuru, India, on its patented respiratory illness prevention technology in collaboration ...

Core Insights - Mangoceuticals, Inc. has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc. to market and distribute Dermytol®, a clinically proven skincare treatment aimed at improving skin tone and reducing hyperpigmentation [1][5] Company Overview - Mangoceuticals, Inc. focuses on developing and selling men's wellness products through a secure telemedicine platform, with a growing portfolio that includes various health and wellness solutions [7][8] - Propre Energie, Inc. specializes in plant-based, non-retinol skincare solutions under the Dermytol® brand, emphasizing research and innovation in developing safe and effective products [6] Product Details - Dermytol® is an advanced, plant-based formula designed to address pigmentation issues such as dark spots and uneven skin tone, utilizing a proprietary blend of clinically validated ingredients [2][3] - The formulation includes canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera, providing a safer alternative to traditional skin treatments like hydroquinone [2] Market Insights - The global skincare market is projected to reach approximately $218 billion by 2029, with a compound annual growth rate (CAGR) of 3.61% from 2025 to 2029 [4] - The plant-based skincare segment is expected to grow from $789.75 million in 2023 to $1.62 billion by 2033, reflecting a robust CAGR of 7.5% over the next decade, driven by consumer demand for natural and effective skincare solutions [4] Strategic Partnership - The partnership allows Mangoceuticals to leverage its marketing and distribution infrastructure to accelerate Dermytol®'s penetration in North and South American markets, with the product available in both patch and cream formulations [5]

Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx’s intellectual property portfolio highlights the Company’s commitment to innovative solutions that su ...